{"identifier":"/us/usc/t21/s825","title_num":"21","num":"§ 825.","heading":"Labeling and packaging","status":null,"guid":"id5f37956b-ceff-11e7-ac08-9eab3197d358","source_credit":"(Pub. L. 91–513, title II, § 305, Oct. 27, 1970, 84 Stat. 1256; Pub. L. 113–260, § 3(a), Dec. 18, 2014, 128 Stat. 2931.)","seq_in_title":458,"parent_identifier":"/us/usc/t21/ch13/schI/ptC","ancestors":[{"identifier":"/us/usc/t21","level":"title","num":"Title 21—","heading":"FOOD AND DRUGS","status":null,"is_section":false},{"identifier":"/us/usc/t21/ch13","level":"chapter","num":"CHAPTER 13—","heading":"DRUG ABUSE PREVENTION AND CONTROL","status":null,"is_section":false},{"identifier":"/us/usc/t21/ch13/schI","level":"subchapter","num":"SUBCHAPTER I—","heading":"CONTROL AND ENFORCEMENT","status":null,"is_section":false},{"identifier":"/us/usc/t21/ch13/schI/ptC","level":"part","num":"Part C—","heading":"Registration of Manufacturers, Distributors, and Dispensers of Controlled Substances","status":null,"is_section":false}],"xml":"<section xmlns=\"http://xml.house.gov/schemas/uslm/1.0\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xmlns:dc=\"http://purl.org/dc/elements/1.1/\" xmlns:dcterms=\"http://purl.org/dc/terms/\" style=\"-uslm-lc:I80\" id=\"idec8e0a2d-0c74-11e6-b5d4-9376778ac99d\" identifier=\"/us/usc/t21/s825\"><num value=\"825\">§ 825.</num><heading> Labeling and packaging</heading><subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idec8e0a2e-0c74-11e6-b5d4-9376778ac99d\" identifier=\"/us/usc/t21/s825/a\"><num value=\"a\" class=\"bold\">(a)</num><heading class=\"bold\"> Symbol</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">It shall be unlawful to distribute a controlled substance in a commercial container unless such container, when and as required by regulations of the Attorney General, bears a label (as defined in <ref href=\"/us/usc/t21/s321/k\">section 321(k) of this title</ref>) containing an identifying symbol for such substance in accordance with such regulations. A different symbol shall be required for each schedule of controlled substances.</p>\n</content>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idec8e0a2f-0c74-11e6-b5d4-9376778ac99d\" identifier=\"/us/usc/t21/s825/b\"><num value=\"b\" class=\"bold\">(b)</num><heading class=\"bold\"> Unlawful distribution without identifying symbol</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">It shall be unlawful for the manufacturer of any controlled substance to distribute such substance unless the labeling (as defined in <ref href=\"/us/usc/t21/s321/m\">section 321(m) of this title</ref>) of such substance contains, when and as required by regulations of the Attorney General, the identifying symbol required under subsection (a).</p>\n</content>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idec8e0a30-0c74-11e6-b5d4-9376778ac99d\" identifier=\"/us/usc/t21/s825/c\"><num value=\"c\" class=\"bold\">(c)</num><heading class=\"bold\"> Warning on label</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">The Secretary shall prescribe regulations under <ref href=\"/us/usc/t21/s353/b\">section 353(b) of this title</ref> which shall provide that the label of a drug listed in schedule II, III, or IV shall, when dispensed to or for a patient, contain a clear, concise warning that it is a crime to transfer the drug to any person other than the patient.</p>\n</content>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idec8e0a31-0c74-11e6-b5d4-9376778ac99d\" identifier=\"/us/usc/t21/s825/d\"><num value=\"d\" class=\"bold\">(d)</num><heading class=\"bold\"> Containers to be securely sealed</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">It shall be unlawful to distribute controlled substances in schedule I or II, and narcotic drugs in schedule III or IV, unless the bottle or other container, stopper, covering, or wrapper thereof is securely sealed as required by regulations of the Attorney General.</p>\n</content>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"idec8e0a32-0c74-11e6-b5d4-9376778ac99d\" identifier=\"/us/usc/t21/s825/e\"><num value=\"e\" class=\"bold\">(e)</num><heading class=\"bold\"> False labeling of anabolic steroids</heading><paragraph style=\"-uslm-lc:I11\" class=\"indent0\" id=\"idec8e0a33-0c74-11e6-b5d4-9376778ac99d\" identifier=\"/us/usc/t21/s825/e/1\"><num value=\"1\">(1)</num><content> It shall be unlawful to import, export, manufacture, distribute, dispense, or possess with intent to manufacture, distribute, or dispense, an anabolic steroid or product containing an anabolic steroid, unless the steroid or product bears a label clearly identifying an anabolic steroid or product containing an anabolic steroid by the nomenclature used by the International Union of Pure and Applied Chemistry (IUPAC).</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I11\" class=\"indent0\" id=\"idec8e0a34-0c74-11e6-b5d4-9376778ac99d\" identifier=\"/us/usc/t21/s825/e/2\"><num value=\"2\">(2)</num><subparagraph style=\"-uslm-lc:I11\" class=\"indent0\" id=\"idec8e0a35-0c74-11e6-b5d4-9376778ac99d\" identifier=\"/us/usc/t21/s825/e/2/A\"><num value=\"A\">(A)</num><content> A product described in subparagraph (B) is exempt from the International Union of Pure and Applied Chemistry nomenclature requirement of this subsection if such product is labeled in the manner required under the Federal Food, Drug, and Cosmetic Act [<ref href=\"/us/usc/t21/s301\">21 U.S.C. 301</ref> et seq.].</content>\n</subparagraph>\n<subparagraph style=\"-uslm-lc:I11\" class=\"indent0\" id=\"idec8e0a36-0c74-11e6-b5d4-9376778ac99d\" identifier=\"/us/usc/t21/s825/e/2/B\"><num value=\"B\">(B)</num><chapeau> A product is described in this subparagraph if the product—</chapeau><clause style=\"-uslm-lc:I12\" class=\"indent1\" id=\"idec8e0a37-0c74-11e6-b5d4-9376778ac99d\" identifier=\"/us/usc/t21/s825/e/2/B/i\"><num value=\"i\">(i)</num><content> is the subject of an approved application as described in section 505(b) or (j) of the Federal Food, Drug, and Cosmetic Act [<ref href=\"/us/usc/t21/s355/b\">21 U.S.C. 355(b)</ref>, (j)]; or</content>\n</clause>\n<clause style=\"-uslm-lc:I12\" class=\"indent1\" id=\"idec8e0a38-0c74-11e6-b5d4-9376778ac99d\" identifier=\"/us/usc/t21/s825/e/2/B/ii\"><num value=\"ii\">(ii)</num><chapeau> is exempt from the provisions of section 505 of such Act relating to new drugs because—</chapeau><subclause style=\"-uslm-lc:I13\" class=\"indent2\" id=\"idec8e0a39-0c74-11e6-b5d4-9376778ac99d\" identifier=\"/us/usc/t21/s825/e/2/B/ii/I\"><num value=\"I\">(I)</num><content> it is intended solely for investigational use as described in section 505(i) of such Act; and</content>\n</subclause>\n<subclause style=\"-uslm-lc:I13\" class=\"indent2\" id=\"idec8e0a3a-0c74-11e6-b5d4-9376778ac99d\" identifier=\"/us/usc/t21/s825/e/2/B/ii/II\"><num value=\"II\">(II)</num><content> such product is being used exclusively for purposes of a clinical trial that is the subject of an effective investigational new drug application.</content>\n</subclause>\n</clause>\n</subparagraph>\n</paragraph>\n</subsection>\n<sourceCredit id=\"idec8e0a3b-0c74-11e6-b5d4-9376778ac99d\">(<ref href=\"/us/pl/91/513/tII\">Pub. L. 91–513, title II</ref>, § 305, <date date=\"1970-10-27\">Oct. 27, 1970</date>, <ref href=\"/us/stat/84/1256\">84 Stat. 1256</ref>; <ref href=\"/us/pl/113/260\">Pub. L. 113–260</ref>, § 3(a), <date date=\"2014-12-18\">Dec. 18, 2014</date>, <ref href=\"/us/stat/128/2931\">128 Stat. 2931</ref>.)</sourceCredit>\n<notes type=\"uscNote\" id=\"idec8e0a3c-0c74-11e6-b5d4-9376778ac99d\">\n<note style=\"-uslm-lc:I75\" topic=\"referencesInText\" id=\"idec8e0a3d-0c74-11e6-b5d4-9376778ac99d\">\n<heading class=\"centered smallCaps\">References in Text</heading><p style=\"-uslm-lc:I21\" class=\"indent0\">Schedules I, II, III, and IV, referred to in subsecs. (c) and (d), are set out in <ref href=\"/us/usc/t21/s812/c\">section 812(c) of this title</ref>.</p>\n<p style=\"-uslm-lc:I21\" class=\"indent0\">The Federal Food, Drug, and Cosmetic Act, referred to in subsec. (e)(2)(A), is <ref href=\"/us/act/1938-06-25/ch675\">act June 25, 1938, ch. 675</ref>, <ref href=\"/us/stat/52/1040\">52 Stat. 1040</ref>, which is classified generally to chapter 9 (§ 301 et seq.) of this title. For complete classification of this Act to the Code, see <ref href=\"/us/usc/t21/s301\">section 301 of this title</ref> and Tables.</p>\n</note>\n<note style=\"-uslm-lc:I74\" topic=\"amendments\" id=\"idec8e0a3e-0c74-11e6-b5d4-9376778ac99d\"><heading class=\"centered smallCaps\">Amendments</heading><p style=\"-uslm-lc:I21\" class=\"indent0\">2014—Subsec. (e). <ref href=\"/us/pl/113/260\">Pub. L. 113–260</ref> added subsec. (e).</p>\n</note>\n<note style=\"-uslm-lc:I74\" topic=\"effectiveDate\" id=\"idec8e0a3f-0c74-11e6-b5d4-9376778ac99d\"><heading class=\"centered smallCaps\">Effective Date</heading><p style=\"-uslm-lc:I21\" class=\"indent0\">Section effective on first day of seventh calendar month that begins after <date date=\"1970-10-26\">Oct. 26, 1970</date>, but with Attorney General authorized to postpone such effective date for such period as he might determine to be necessary for the efficient administration of this subchapter, see <ref href=\"/us/pl/91/513/s704/c\">section 704(c) of Pub. L. 91–513</ref>, set out as a note under <ref href=\"/us/usc/t21/s801\">section 801 of this title</ref>.</p>\n</note>\n<note style=\"-uslm-lc:I74\" topic=\"miscellaneous\" id=\"idec8e0a40-0c74-11e6-b5d4-9376778ac99d\"><heading class=\"centered smallCaps\">Identification and Publication of List of Products Containing Anabolic Steroids</heading><p><ref href=\"/us/pl/113/260\">Pub. L. 113–260</ref>, § 4, <date date=\"2014-12-18\">Dec. 18, 2014</date>, <ref href=\"/us/stat/128/2932\">128 Stat. 2932</ref>, provided that:<quotedContent origin=\"/us/pl/113/260\">\n<subsection style=\"-uslm-lc:I21\" class=\"indent0\"><num value=\"a\">“(a)</num><heading> <inline class=\"small-caps\">In General</inline>.—</heading><content>The Attorney General may, in the Attorney General’s discretion, collect data and analyze products to determine whether they contain anabolic steroids and are properly labeled in accordance with this Act [see <ref href=\"/us/pl/113/260/s1\">section 1 of Pub. L. 113–260</ref>, set out as a Short Title of 2014 Amendment note under <ref href=\"/us/usc/t21/s801\">section 801 of this title</ref>] and the amendments made by this Act. The Attorney General may publish in the Federal Register or on the website of the Drug Enforcement Administration a list of products which the Attorney General has determined, based on substantial evidence, contain an anabolic steroid and are not labeled in accordance with this Act and the amendments made by this Act.</content>\n</subsection>\n<subsection style=\"-uslm-lc:I21\" class=\"indent0\"><num value=\"b\">“(b)</num><heading> <inline class=\"small-caps\">Absence From List</inline>.—</heading><content>The absence of a product from the list referred to in subsection (a) shall not constitute evidence that the product does not contain an anabolic steroid.”</content>\n</subsection>\n</quotedContent>\n</p>\n</note>\n</notes>\n</section>","provision":null,"duplicates":[],"release":{"label":"115-84","currency_date":"2017-11-17","congress":115,"law_num":84,"excluded_laws":[],"update_num":null,"seq":119,"is_partial":false,"caveat":null,"titles_affected":["05","10","21","38","42","46"],"ingested_titles":[]},"served_from":{"label":"115-84","currency_date":"2017-11-17","congress":115,"law_num":84,"excluded_laws":[],"update_num":null,"seq":119,"is_partial":false,"caveat":null,"titles_affected":["05","10","21","38","42","46"],"ingested_titles":[]},"content_first_seen":{"label":"114-146","currency_date":"2016-04-19","congress":114,"law_num":146,"excluded_laws":[],"update_num":null,"seq":66,"is_partial":false,"caveat":null,"titles_affected":["01","02","03","04","05a","15","16","21","42"],"ingested_titles":[]},"is_exact":true,"note":null}